Strong Albumin Solutions in Patients With Septic Shock
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Sepsis is an increasingly recognised burden to healthcare systems worldwide. Intravenous
fluid therapy is a common first-line intervention recommended by international guidelines.
Hyperoncotic preparations of human albumin solution are widely available, but their efficacy
has yet to be proven.
This randomised feasibility trial will test whether it is feasible to administer hyperoncotic
albumin solutions as both fluid resuscitation and as a regular supplement in patients with
early septic shock.